|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, the current case may provide a possible link between TTP and G-CSF-producing tumor.
|
31479879 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
MDSC were strongly induced in orthotopic KPC-derived pancreatic cancer, and frequencies of MDSC subsets correlated with tumor weight and G-CSF serum levels, whereas other immune cell populations decreased.
|
31694706 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In vitro and in vivo experiments revealed that tumor-derived G-CSF and G-CSF-mediated IL-6 production from the tumor microenvironment are involved in the development of leukocytosis and thrombocytosis in patients with endometrial cancer.
|
31741758 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
On the other hand, mice bearing non-metastatic 67NR tumors showed no elevation in neutrophil counts and displayed low expression levels of G-CSF and IL-1β in their tumors.
|
31552036 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A Pilot, Exploratory, Randomized, Phase II Safety Study Evaluating Tumor Cell Mobilization and Apheresis Product Contamination in Patients Treated with Granulocyte Colony-Stimulating Factor Alone or Plus Plerixafor.
|
30149148 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
However, overexpression of G-CSF has been implicated in several important processes in tumor biology such as tumor growth, angiogenesis, and metastasis.
|
31522450 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The patients with TRL-positive cervical cancer displayed upregulated tumor G-CSF expression, elevated G-CSF levels, and increased MDSC frequencies in the peripheral blood compared with the TRL-negative patients.
|
29752277 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Trials demonstrating improved outcomes with high-dose cytarabine, addition of cladribine, or escalated anthracycline doses prompted a phase 1/2 study (NCT02044796) of G-CSF, cladribine, high-dose cytarabine, and dose-escalated mitoxantrone (GCLAM) in adults with newly-diagnosed AML or other high-grade myeloid neoplasms.
|
29720734 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Cytokine profiling of CRPC tumor grafts exposed to GSNO revealed a significant decrease in expression of G-CSF and M-CSF compared with grafts not exposed to GSNO.
|
30322928 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These results indicate that intratumoral granulocyte-colony stimulating factor expression and CD11b<sup>high</sup>/Gr-1<sup>high</sup> PMN-MDSC recruitment underlie tumor resistance to anti-VEGF therapy, and suggest PyNPases are potentially useful targets during anti-angiogenic therapy.
|
29707135 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Biological function and underlying mechanistic investigations were carried out using SGC7901 cell lines, and the effects of G-CSF on tumor proliferation, migration, and tube formation were examined.
|
29567938 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor-derived granulocyte colony-stimulating factor diminishes efficacy of breast tumor cell vaccines.
|
30348199 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The first biosimilars developed in oncology were the supportive-care agents filgrastim and epoetin.
|
29707043 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Use of Granulocyte-colony Stimulating Factor During Chemotherapy and Its Association With CA27.29 and Circulating Tumor Cells-Results From the SUCCESS A Trial.
|
30017795 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The use of highly loaded G-CSF NPs as immune adjuvants could enhance the antitumor activity of therapeutic monoclonal antibodies by amplifying tumor cell destruction by innate immune cells.
|
29283559 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In two TNBC mouse models, 4T1 and Py8119, glycolysis restriction inhibits tumor granulocyte colony-stimulating factor (G-CSF) and granulocyte macrophage colony-stimulating factor (GM-CSF) expression and reduces MDSCs.
|
29805099 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Deletion of <i>csf3</i> in PDAC cells or use of a G-CSF-blocking antibody decreased tumor growth.
|
28775207 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
An advanced granulocyte-colony stimulating factor (G-CSF)-producing tumor is rare, and it exhibits leukocytosis in association with high serum G-CSF levels.
|
28789371 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
It has been shown that Granulocyte colony-stimulating factor (G-CSF) has a higher expression in malignant tumors, and anti-G-CSF therapy considerably decreases tumor growth, tumor vascularization and metastasis.
|
28646705 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumour-initiating cells (TICs) exhibit elevated G-CSF.
|
27183469 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Therefore, these data suggest that G-CSF may contribute to tumor growth and decrease the antitumor effect of radiotherapy, possibly by promoting vascularization in cancer lesions.
|
25976379 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Despite being a known growth factor, the impact of G-CSF on solid tumours has not been well examined.
|
24448357 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, G-CSF can promote tumors by inhibiting innate and adaptive immunity and enhancing angiogenesis and neoplastic growth.
|
23674093 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition, a G-CSF independent downregulation of Bv8 was found as a common target of all three DmiRs and correlated with decreased tumor recruitment of bone marrow-derived CD11b+ Gr-1+ myeloid cells.
|
22952847 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We investigated plasma levels of selected hematopoietic cytokines: stem cell factor (SCF), granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF), and macrophage colony-stimulating factor (M-CSF) and the tumor marker cancer antigen (CA 125) in epithelial ovarian cancer patients as compared with control groups: benign ovarian tumor patients (cysts) and healthy subjects.
|
22988839 |
2012 |